GlassScriptPhysician profile
Susan W Ade
NPI 1447447008
$2,895.87
in general payments reported to CMS, 2019-2025
22 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 83% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
See the full distribution for Gerontology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $233 · 2023: $417 · 2024: $989 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $879.74 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $430.01 | 2021-2025 | Mounjaro, Zepbound, Amyvid |
| Abbvie INC. | $365.32 | 2021-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.12 | 2024-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.06 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $153.82 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $97.47 | 2024-2025 | |
| Novo Nordisk INC | $88.00 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $76.87 | 2024-2025 | Prolia, Evenity, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $64.11 | 2021-2022 | |
| Pfizer INC. | $61.80 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $41.68 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $39.06 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $38.46 | 2021-2023 | Steglatro, Belsomra |
| Madrigal Pharmaceuticals | $38.07 | 2025 | Rezdiffra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.45 | 2021 | |
| Shield Therapeutics INC | $24.24 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $22.47 | 2025 | Eliquis |
| Lundbeck LLC | $20.73 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $20.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.41 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $16.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.